Investor webinar 5 September 2017
1, September, 2017
Admedus Limited (ASX: AHZ) held an investor webinar on 5 September, 2017 to discuss the results of the Company’s Preliminary Final Report (Appendix 4E) for the year ended 30 June 2017. Admedus CEO Wayne Paterson will provide a review of the Company’s year-end performance as well as operational and business highlights.
Admedus announces exclusive supply agreement with 4C Medical
31, August, 2017
Admedus Limited is pleased to announce that it has entered an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Read more here.
Sponsorship supports kids with heart disease
15, August, 2017
Admedus Ltd is proud to announce a six-month $20k sponsorship of the HeartKids Education Program which provides vital resources for families of children living with congenital/childhood heart disease. In Australia, congenital/childhood heart disease is the leading cause of death for children under a year old and nearly three thousand babies are born with a heart […]
Admedus attracts keen interest from surgeons at symposium
11, July, 2017
Professor Leon Neethling recently attended the 53rd Annual Meeting of the Japanese Society of Paediatric Cardiology and Cardiac Surgery, in Hamamatsu, where he presented at a lunch symposium to more than 180 congenital surgeons from Japan, Vietnam, Philippines, Malaysia, Taiwan and Korea about our ADAPT products as part of the 13th Japan-China-Korea Paediatric Heart Forum.